Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00196404 | Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder | PHASE2 | COMPLETED | 800 | — | — | Oct 1, 2004 | Dec 1, 2006 | Aug 20, 2012 | 48 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DR-3001a | DRUG | 4mg daily vaginally |
| DR-3001b | DRUG | 6 mg vaginally daily |
| Placebo | OTHER | Administered vaginally to match experimental arms |
Inclusion Criteria: * Diagnosis of overactive bladder and incontinence for at least 6 months * Using birth control or menopausal * Willing to discontinue current medication for overactive bladder Exclusion Criteria: * Pregnant or given birth in the last 6 months * Three or more urinary tract infe...